Notice of Winter Holidays

Mediplus Pharmaceuticals Co., Ltd. will be closed for winter holidays from Thursday, December 28, 2024, to Sunday, January 5, 2025.

During this period, we will continue to receive inquiries via fax and email; however, please note that we will not be responding to inquiries or processing orders until we resume operations.

We apologize for any inconvenience this may cause and appreciate your understanding.

Our Director’s Interview Featured in WWD BEAUTY JAPAN

In the August 26, 2024 issue of WWD BEAUTY(published by WWD JAPAN) an interview with our Director and Executive Fellow, Gotaro Shioda, was featured under the title “The Potential of ‘Ozonized Glycerin’ for Dramatic Skin Regeneration Without Side Effects” in the article “BEAUTY RESEARCHERS Vol.8”.

Read more

Presentation on the Efficacy of Novel Glycerin Compounds for Atopic Dermatitis at AAD

A presentation on the safety and efficacy evaluation of atopic dermatitis was held at the American Academy of Dermatology (AAD) in March, and it has been featured in the “Health Industry Distribution Newspaper” issue 1111 (published on 4/25).

We plan to continue utilizing Novel Glycerin Compounds (ozonized glycerin) extensively in the business ventures undertaken by our group companies in the future.

For the AAD presentation release, please visit:

Announcement of New Patent Information Page Launch

We are pleased to announce the launch of our new patent information page.
PATENT
This page provides disclosures of the patent registration information that we possess. Interested parties are invited to explore this resource to better understand it further.

50th Anniversary

Mediplus Pharma, Inc. had celebrated its 50th anniversary on March 13.
We would like to express our sincere gratitude for your support and loyal patronage.
We have consistently conducted research and development on the theme of “ozone”, a substance that can contribute to the global environment since our founding.
Currently, our business domain is based on the cosmetics business for skin care, and we will continue to develop with the aim of developing pharmaceuticals for humans and animals.
All of our employees will continue to make further efforts to respond to your kindness and expectations.
Your continued support will be highly appreciated.